Come together for Congress '23

BSAVA 2023

Early bird registration closes on 26 January

Don't delay...
book your tickets now!

www.bsavaevents.com/bsavacongress2023

ORIGINAL ARTICLE

Usefulness of cardiac biomarker screening to detect dilated cardiomyopathy in Dobermanns

J. Dukes-McEwan [1,*], K. E. Garven[†], J. Lopez Alvarez[‡], P. Oliveira[‡], P. F. Motskula[§] and R. Willis[¶]

*Department of Small Animal Clinical Science, School of Veterinary Science, Leahurst Campus, University of Liverpool, Chester High Road, Neston CH64 7TE, UK
[†]MBM Veterinary Group, 21 Hill Street, Kilmarnock, KA3 1HF, UK
[‡]Davies Veterinary Specialists, Manor Farm Business Park, Higham Gobion, Hitchin, Herts SG5 3HR, UK
[§]Anderson-Moores Veterinary Specialists, The Granary, Bunstead Barns, Poles Ln, Hursley, Winchester SO21 2LL, UK
[¶]Holter Monitoring Services, Dick White Referrals, Station Farm, London Road, Six Mile Bottom, Cambridgeshire CB8 0UH, UK

[1]Corresponding author email: j.dukes-mcewan@liverpool.ac.uk
J. Lopez Alvarez's current address is Memvet – Centre de Referència Veterinària. C/Reina Esclaramunda 6, baixos, 07003 Palma, Mallorca, Illes Balears; Fundació Hospital Clínic Veterinari de la Universitat Autònoma de Barcelona. Campus UAB, Carrer de l'Hospital, s/n, 08193 Cerdanyola del Vallès, Barcelona; Telemedicine Consultant at IDEXX, UK
P.F. Motskula's current address is Vetekar – Veterinary Cardiology Consultancy. Fortuuna 35-24, Tartu 50603, Estonia; Institute of Veterinary Medicine and Animal Sciences, Estonian University of Life Sciences, Kreutzwaldi 62, 51006 Tartu, Estonia; Telemedicine Consultant at IDEXX, UK
R. Willis's current address is Sarah Smith Veterinary Cardiology; Ivy Court, Willington Rd, Etwall, Derby DE65 6JG, UK

Objectives: To assess the diagnostic accuracy of two cardiac biomarker assays (N-terminal pro-BNP, Troponin I) in detecting dilated cardiomyopathy in Dobermanns.

Materials and Methods: Dobermanns undergoing cardiac biomarker testing were screened by echocardiography and Holter monitoring, then assigned to a group: normal, equivocal, arrhythmia form of dilated cardiomyopathy, echocardiographic form of dilated cardiomyopathy or both. Some were reassessed to identify final status. Initial cardiac biomarker results were compared to final status. Receiver operating characteristic curves were used to identify area under the curve and corresponding sensitivity (Se), specificity (Sp) for different cut-offs (CO) for each cardiac biomarker.

Results: A total of 118 Dobermanns with cardiac biomarker data had echocardiography/Holter assessment. Repeat assessment was carried out in 47 Dobermanns after 394.5 ±151.0 days. Seventeen dogs changed group between initial and final status. The final status of 59 was normal, nine were equivocal and 50 had dilated cardiomyopathy (prevalence 42.4%). Of the dilated cardiomyopathy group, 25 had dilated cardiomyopathy-both, 13 dilated cardiomyopathy-echocardiography and 12 dilated cardiomyopathy-Holter. Receiver operating characteristic area under the curve=0.807 for N-terminal proBNP (Se 0.69 and Sp 0.81) and 0.873 for high-sensitivity cardiac Troponin I (Se 0.77 and Sp 0.86). When both Se and Sp were optimised for all forms of dilated cardiomyopathy, N-terminal proBNP cut-off was 626 pmol/L (Se and Sp 0.79) and high-sensitivity cardiac Troponin I cut-off was 0.056 ng/mL (Se and Sp 0.84). Receiver operating characteristic area under the curve was higher for dilated cardiomyopathy-echocardiography (NT-proBNP 0.883; high-sensitivity cardiac Troponin I 0.907) than dilated cardiomyopathy-Holter.

Clinical Significance: Cardiac biomarker screening may be useful to select Dobermanns which would benefit from further assessment by echocardiography and Holter.

BSAVA JOURNAL OF SMALL ANIMAL PRACTICE JSAP

Journal of Small Animal Practice (2022) **63**, 275–285
DOI: 10.1111/jsap.13455

Accepted: 16 November 2021; Published online: 13 December 2021

INTRODUCTION

Dilated cardiomyopathy (DCM) has a high prevalence in the Dobermann breed (Wess *et al.* 2010b). DCM is familial but inheritance is complex (Simpson *et al.* 2015) with several loci or genes reported (Mausberg *et al.* 2011, Meurs *et al.* 2012, Owczarek-Lipska *et al.* 2013, Meurs *et al.* 2019). Therefore, a simple genetic test therefore cannot reliably identify Dobermanns at risk of developing DCM. Owners, breeders and veterinary surgeons therefore still need to rely on clinical screening tools to identify individual Dobermanns with DCM.

Dobermann DCM is associated with ventricular arrhythmias, which may or may not be associated with the echocardiographic changes typical of DCM (Wess *et al.* 2017). Affected Dobermanns with DCM have a long, preclinical (occult) phase lasting years and it is important to identify these individuals to avoid breeding from affected dogs and also to benefit the individual dog (Summerfield *et al.* 2012). Current "gold standard" recommendations for screening Dobermanns for DCM are regular echocardiography and Holter monitoring (Wess *et al.* 2017). The accuracy of cardiac biomarkers (CBMs) for DCM has been investigated; Wess and colleagues showed that the CBMs Troponin I (Immulite 2000 troponin I test; Siemens Healthcare Diagnostics) (Wess *et al.* 2010c) and N-terminal pro-brain natriuretic peptide [Cardiopet proBNP test, IDEXX Laboratories (first-generation assay)] (NTproBNP) (Wess *et al.* 2011) each separately showed reasonable sensitivity and specificity at detecting clinical and pre-clinical Dobermann DCM. They also identified incipient cases, *i.e.* those which were initially normal but later developed echocardiographic or Holter abnormalities. An ultrasensitive Troponin I (Advia Centaur TnI-Ultra assay; Siemens Healthcare Diagnostics) assay provided greater sensitivity at detecting incipient cases, which developed DCM within 18 months of "last normal" screening (Klüser *et al.* 2019). The second-generation NTproBNP assay [Cardiopet proBNP test, IDEXX Laboratories (second-generation assay); IDEXX Laboratories] has been assessed prospectively in Dobermanns, along with the ultrasensitive Troponin I (Advia Centaur TnI-Ultra assay; Siemens Healthcare Diagnostics) assay and the PDK4 genetic test (Gordon *et al.* 2015).

To date there are no published reports of the Beckman Coulter Access high sensitivity cTnI assay (Beck- man Coulter Access hsTnI assay; IDEXX Laboratories) being used prospectively in Dobermanns to identify preclinical DCM although it has been used to generate canine reference ranges including Dobermanns (Oyama & Sisson 2004).

We hypothesised that CBM screening with both the hs cTnI assay (Beckman Coulter Access hsTnI assay; IDEXX Laboratories) and second-generation NTproBNP assay [Cardiopet proBNP test, IDEXX Laboratories (second-generation assay); IDEXX Laboratories] would improve the sensitivity and specificity of detection and discrimination between DCM-affected and healthy Dobermanns better than either test alone.

Study aims were (1) to investigate the sensitivity and specificity of the hs cTnI (Beckman Coulter Access hsTnI assay; IDEXX Laboratories) assay in identifying Dobermanns with DCM compared with echocardiography and Holter monitoring; (2) to report on the sensitivity and specificity of the NTproBNP [Cardiopet proBNP test, IDEXX Laboratories (second-generation assay); IDEXX Laboratories] assay in identifying UK Dobermanns with DCM compared with echocardiography and Holter monitoring; (3) to investigate whether the combination of hs cTnI and second-generation NTproBNP improves identification of DCM.

MATERIALS AND METHODS

This was a prospective, observational study. The CBM study was conducted between January 2015 and January 2017. Institutional ethical approval had been awarded (VREC164).

Dobermanns with CBM data available were eligible for inclusion. During the study period, physical examination and blood sampling was carried out at Dobermann shows by a veterinary surgeon. Blood samples were taken into EDTA for NTproBNP and either serum or EDTA tubes for hs cTnI (Klüser *et al.* 2019). Samples were centrifuged within 1 hour, and plasma/serum separated and stored at −20°C or −4°C prior to shipping to the laboratory within 24 hours, at ambient temperature.

Dobermanns who presented for evaluation by a participating cardiologist were also eligible if contemporaneous CBM results were available. Some cases had clinical signs which prompted the cardiovascular assessment and others presented for routine DCM screening by echocardiography and Holter monitoring (Echo/Holter).

Dogs with hs cTnI {ref. <0.07 ng/mL [Personal communication: Anne-Marie Porritt; IDEXX Laboratories (hs cTnI reference range generated from a collaboration with the Royal Veterinary College)]} and/or NTproBNP (ref. <735 pmol/L (Gordon *et al.* 2013)) concentrations above the laboratory reference ranges were included in the abnormal CBM group. Dobermanns in the normal CBM group had both hs cTnI and NTproBNP concentrations within reference ranges. From the normal CBM group, Dobermanns were selected from show testing and invited for Echo/Holter if they were ≥4 years old, had an unremarkable physical examination documented by the attending veterinary surgeon and were considered to be healthy by their owners. The age of ≥4 years old was selected so that the screened population was likely to have a higher prevalence of DCM to minimise false-negative results with the screening tests. For Dobermanns presenting to a cardiologist, any age was permitted, provided that CBM results and echo/Holter data were available and any non-cardiac condition was noted.

Echo was carried out by veterinarians with a post-graduate qualification in cardiology following two-dimensional (2D) and M-mode recommendations as previously described (Wess *et al*. 2010a,b, 2017). Doppler echocardiographic studies (colour flow and spectral) were sufficiently detailed to exclude other congenital or acquired cardiac diseases.

Holter recordings were scheduled to be over approximately 24 hours, and studies of <18 hours were excluded. Analysis of the Holter recordings was by a single author (RW). Ambulatory ECG recording data were acquired using a commercial ambulatory ECG monitor [Lifecard Compact Flash (CF); Spacelabs Healthcare] at a sampling frequency of 1024 Hz and stored on a 90 megabyte removable CF card. Commercially available Holter software (Pathfinder version 9; Spacelabs Healthcare) was used to perform standardised semi-automatic arrhythmia analysis. From the Holter analyses, Dobermanns were considered to be normal if they had fewer than 50 ventricular premature complexes (VPCs) over 24 hours, abnormal if they had >100 VPCs/24 hours, and equivocal if they had 50 to 100 VPCs/24 hours (Wess et al. 2010b). The total number of VPCs and their complexity (couplets, triplets, salvos or runs of ventricular tachycardia) were noted (Wess *et al*. 2017). If couplets, triplets or runs were closely coupled (instantaneous rate > 250 bpm) but the absolute VPC/24-hour count was <50, these were classified as equivocal.

Based on Echo/Holter results, Dobermanns were classified as follows:

1. Apparently healthy (no echo or Holter abnormalities)
2. DCM-Echo: Echo abnormal; presence of congestive heart failure noted: DCM-CHF
3. DCM-Holter: Holter abnormal or atrial fibrillation (AF)
4. DCM-Both: Both Echo/Holter Abnormal (with or without DCM-CHF)
5. Equivocal (for either Echo or Holter or both).

After 12 months, a number of dogs were invited back from the apparently healthy and equivocal groups for repeat screening by CBMs and Echo/Holter. In particular, Dobermanns with abnormal CBM test(s) but initially unremarkable echocardiography and Holter monitoring results were re-examined. Dobermanns from the DCM groups were also reassessed as clinically indicated. Owner updates were sought at the end of the study (January 2019), to provide information about the final status of their dog (alive, dead, cause of death if known). Cause of death was categorised as sudden, cardiac (death or euthanasia due to cardiac causes) and other (non-cardiac).

Statistical analysis

Data from each dog were collated in an Excel spreadsheet (2016; Microsoft Office) and statistical analyses were carried using SigmaPlot 14 (Systat). To include data from animals with CBM results below the detection limit of the assays, for NTproBNP, values reported as <250 pmol/L were assigned a value of 249, and for hs cTnI, values reported as <0.01 ng/mL were assigned a value of 0.009. If NT-pro-BNP was >10,000 pmol/L, it was assigned a value of 10,001. The Shapiro–Wilk test was used to assess for normal distribution of data spread and the Brown-Forsythe test was used to test for equal variance. Basic descriptive statistics for normally distributed data included mean and standard deviation or median (interquartile range) for non-normally distributed data or if data showed unequal variance. To compare continuous normally distributed data for two groups (*e.g*. male/female), the unpaired *t*-test was used. To compare three or more groups with normally distributed data, one-way analysis of variance (ANOVA) was used with the Holm-Sidak test for multiple pairwise comparisons. If data were not normally distributed, the Kruskal-Wallis ANOVA on ranks was used, with Dunn's method for multiple pairwise comparisons. Categorical data (*e.g*. males, females) were compared using the chi-squared test. To explore for any associations (*e.g*. age, CBM data), scatter plots were constructed. As CBM data were not normally distributed, Spearman's rank order correlation was used to investigate presence, strength and significance of any associations.

The initial CBM results were compared with the final known status of the dog (NORMAL, EQUIVOCAL, DCM-echo, DCM-Holter, DCM-Both) and noted to be concordant or discordant with the final diagnosis. Incipient results were included (*i.e*. normal echo and Holter at time of first CBM sampling, but later developed echo and/or Holter evidence of DCM on repeat assessment).

Receiver operating characteristic (ROC) curves were constructed for each of the initial hs cTnI and NTproBNP results and including the final diagnosis for each dog as DCM (all forms) or Normal; Dobermanns with equivocal echo or Holter data were excluded from this analysis. Area under the curve (AUC) was calculated. To optimise both sensitivity and specificity for all forms of DCM, graphs of sensitivity and specificity for different cut-offs for each biomarker were constructed, and the point at which the curves crossed was selected as the cut-off which optimised both. In addition, similar analyses were applied to DCM-Echo (with or without arrhythmias) and DCM-Holter (with or without echo changes) groups. The cut-offs optimising both sensitivity and specificity for both DCM-echo and DCM-Holter were determined.

Using the prevalence identified in this population (42.4%; see results), from the sensitivity and specificity data for different cut-offs of both CBMs, the positive (PPV) and negative predictive values (NPV) and positive and negative likelihood ratios were determined for each biomarker test being above or below each cut-off. The statistical software determined an optimal operating point from the sensitivity and specificity data, which was calculated as *Sensitivity – m(1-Specificity)*, where *m* is the slope of the tangent to the ROC curve determined by pre-test probability and false positive/false-negative test cost ratio (arbitrarily defined as 1).

RESULTS

A total of 118 Dobermanns were included in the study (Fig 1). Descriptive statistics of their signalment, initial CBM results and final status are shown in Table 1. A total of 50 Dobermanns were



FIG 1. Dobermanns in the study. Flow chart to show the results of Echocardiography and Holter screening following initial cardiac biomarker testing. Some Dobermanns had repeat assessments (n=47 at least two assessments). If they changed group, their interim status is noted (coloured boxes), with numbers which changed groups. Some Dobermanns with DCM changed category of DCM on their repeat assessment (purple arrows); numbers in the black boxes are the final known diagnosis

Table 1. Final recorded status of Dobermanns based on echocardiography and Holter examination and initial cardiac biomarker results

	Normal	DCM-all	DCM-Echo	DCM-Holter	DCM-both	DCM-CHF	Equivocal	P value
n	59	50	13	12	25	10 (9 from DCM-both, 1 from DCM-echo group)	9	n/a
Male/female (n)	21/38	29/21	6/7	5/7	18/7	6/4	6/3	Comparisons: 1: Normal, all DCM **P = 0.032** 2. Normal, Echo DCM, Holter DCM or Both-DCM: **P = 0.024**
Age (years), mean ±sd (inclusion) (min. to max.)	**6.07 ±2.37**[1] (2.13 to 11.02)	7.13 ±2.48 (2.3 to 12.23)	6.18 ±1.93 (3.84 to 10.08)	7.24 ±2.49 (4.04 to 11.42)	**7.86 ±2.44**[1] (2.4 to 12.23)	7.59 ±3.18 (2.4 to 12.23)	6.48 ±1.66 (3.32 to 8.6)	Comparison: Normal, Echo DCM, Holter-DCM, Both DCM and Equivocal; **P = 0.022**
Number dead (type of death)	7 (other or unknown)	34 (14 sudden, 12 cardiac, 9 other)	8 [3 sudden, 2 cardiac (CHF), 3 other]	7 (1 sudden, 2 cardiac, 4 other)	19 (10 sudden, 8 cardiac, 1 other)	9 (4 sudden, 8 total cardiac, 1 LTFU)	2 (both other)	Not analysed
Deceased dogs: Timing of death after inclusion (days) (min. to max.)	494.67 ±518.07 (12 to 1149)	439.8 ±337.9 (15 to 1126)	582 ±378.8 (15 to 1126)	702 ±234.4 (386 to 950)	264.79 ±254.16 (1 to 874)	163.89 ±231.25 (1 to 751)	529 and 926 days (n = 2)	Not analysed
Initial NTproBNP result (all in group included), median (range: min. to max.)	**249 (249 to 3140)**[1,4]	1193 (249 to 10,001)	**765.5 (286 to 3209)**[4]	**297 (249 to 5180)**[3]	**2399 (292 to 10,001)**[1,2,3]	4515 (642 to 10,001)	**334 (249 to 1024)** [2]	**P < 0.001**
Initial hs cTnI result (all in group), median (min. to max.)	**0.02 (0.009 to 0.27)**[1,2,3]	0.10 (0.009 to 13.47)	**0.075 (0.02 to 0.27)**[2]	**0.09 (0.009 to 13.47)**[3]	**0.16 (0.06 to 13.47)**[1]	0.27 (0.09 to 1.44)	0.05 (0.02 to 0.1)	**P < 0.001**

CHF Congestive heart failure, echo Echocardiography, hs cTnI High-sensitivity Troponin I, LTFU Lost to follow-up, max Maximum, min Minimum, n/a Not applicable, NTproBNP N-terminal pro-BNP, sd Standard deviation
Cells in bold which share a superscript number are significantly different from each other with post-hoc pairwise comparisons
Abbreviations for GROUPS: All DCM: includes data from Dobermanns with any and all forms of DCM, DCM-echo: DCM evident on echocardiography, DCM-Holter: arrhythmias noted only, DCM-both: meet both the echocardiographic and Holter criteria for diagnosis of DCM. CHF: presence of congestive heart failure (will be in Echo-DCM or Both-DCM groups; not analysed separately)



FIG 2. Box and Whisker plots cardiac biomarker results for Dobermann groups. The line representing the laboratory reference range for each biomarker is indicated. (A) N-terminal pro-BNP concentration (log_{10} scale). The line is the current laboratory 735 pmol/L cut-off. (B) High-sensitivity Troponin I concentration (log_{10} scale). The boxes define the 25th to 75th percentile, with median line shown. Whiskers define the 10th to 90th percentiles, with outlying data points indicated. The line is the current laboratory cut-off of <0.07 ng/mL. Groups: Normal: no abnormalities identified by echocardiography or Holter monitoring at the time of (last) examination. Equivocal: equivocal based on either echocardiography or Holter monitoring results or both; not meeting criteria for normal or DCM groups. Echo-DCM: meets only echocardiographic criteria for diagnosis of DCM; Holter-DCM: meets only arrhythmia criteria for diagnosis of DCM; Both-DCM: meets both echo and Holter criteria for the diagnosis of DCM

documented to have DCM (all forms; DCM-all) implying a prevalence of 42.4%. The dogs from the DCM-both group were older than in the Normal group (P=0.022) and the DCM-both group contained significantly more males (P=0.032).

The data for NTproBNP and hs cTnI concentrations in Table 1 are from the initial assessment. There is a significant difference between the groups for NTproBNP and hs cTnI (both P < 0.001) (Fig 2A, B). There was a modest correlation between NTproBNP and cTnI (Rs = 0.456; P < 0.001). For the normal group of 59 dogs, there was no association between NTproBNP and age, but a modest positive association of hs cTnI concentration and age was identified (Rs = 0.364; P = 0.005).

A total of 17 dogs changed group between initial and final status (Fig 1). The CBM results were separated as being concordant or discordant with the final cardiac status (Table 2). There were four dogs with abnormal NTproBNP (two also with abnormal hs cTnI) who were initially echo/Holter normal, who subsequently developed DCM (two DCM-Echo; two DCM-Holter). An additional dog with abnormal hs cTnI and normal NTproBNP was initially normal but later developed DCM-echo. The numbers in each group at final diagnosis with concordant or discordant CBM results are shown (Table 2).

For the ROC curve analysis, when the laboratory cut-offs for the CBM data were used, the AUC and sensitivity (Se) and specificity (Sp) for all forms of DCM and both CBMs are shown (Table 3; Fig 3A). The AUCs were 0.870 for cTnI and 0.807 for NTproBNP (see Table 3 for the confidence intervals). For the laboratory cut-off of <0.07 ng/mL for cTnI, the Se and Sp were 0.77 and 0.86, respectively. For the cut-off recommended by the laboratory for screening Dobermanns for DCM of <735 pmol/L, Se and Sp were 0.69 and 0.81, respectively (Table 3). When both Se and Sp were optimised, for all forms of DCM, a cut-off for hs cTnI of 0.056 ng/mL and NTproBNP of 626 pmol/L gave both Se and Sp of 0.838 for hs cTnI and 0.787 for NTproBNP, respectively (Table 3). Identification of DCM-echo had greater Se and Sp (cTnI 0.85; NTproBNP 0.81) for slightly higher cut-offs of hs cTnI and NTproBNP with AUCs of 0.907 and 0.883, respectively (Table 3; Fig 3B). Identification of DCM-Holter had slightly lower Se and Sp (hs cTnI 0.846; NTproBNP 0.779) and lower AUCs (0.892 and 0.804), respectively, for their cut-offs (Table 3; Fig 3C).

For the prevalence of DCM (all forms) at 42.4%, the positive likelihood ratio (*i.e.* positive test indicates likelihood of some form of DCM), the negative likelihood ratios and PPV and NPV of the CBM tests at different cut-offs are shown (Table 4). The optimal cut-off points were determined (Table 4; Fig 4A, B).

At the time of data analysis, 42 out of 118 dogs were known to be dead (35.6% of the population). Age of death for all Dobermanns was 8.95 ± 2.5 years. Twenty-six deaths were believed to be cardiac in origin. Of these, 15 deaths were sudden (mainly dying during sleep rather than on exercise), 11 died or were euthanased because of cardiac disease (10 because of congestive heart failure and one because of recurrent syncope affecting the quality of life). For non-cardiac causes of death (n=16), there were eight dogs with neoplasia, two had gastric dilatation/volvulus, three dogs were euthanased due to old age or mobility issues (including one cervical spondylopathy), one due to signs associated with a portosystemic shunt, one bitch died during whelping and two had unknown causes of death. There was no significant difference between the ages of death of normal and the DCM groups (P=0.091).

Table 2. Initial cardiac biomarker results with division of concordant and discordant results with final recorded cardiac status

	Normal	All DCM	DCM-echo	DCM-Holter	DCM-both	DCM-CHF	Equivocal
Number (percentage) of concordant/discordant NT pro-BNP results (initial test)	48 (81.4%)/11 (18.6%)	34 (68%)/16 (32%)	8 (61.4%)/5 (38.5%)	4 (33.3%)/(8 66.7%)	22 (88%)/3 (12%)	9 (90%)/1 (10%) (*the discordant result was in a dog incipient for Echo-DCM*)	Not determined (equivocal final status)
Number (percentage) of concordant/discordant hs cTnI results (initial test)	51 (86.4%)/8 (13.6%)	39 (78%)/11 (22%)	8 (61.4%)/5 (38.5%)	7 (58.3%)/5 (41.7%)	24 (96%)/1 (4%)	10 (100%)/0 (0%)	Not determined (equivocal final status)
Both initial biomarkers concordant? n (percentage)	40 (67.8%)	28 (56%)	5 (38.5%)	2 (16.7%)	22 (88%)	9 (90%)	Not determined (equivocal final status)
Both initial biomarkers discordant? n (percentage)	0	6 (12%) 1 DCM-echo with PSS (NTproBNP 400 pmol/L; hs cTnI 0.03 ng/mL); 1 DCM-both with borderline CBM (NTproBNP 690 pmol/L; hs cTnI 0.06 ng/mL) (also with a cervical neuroendocrine tumour); 4 initially normal, but 2 developed DCM-Holter after 195 (later abnormal CBM) and 363 days later (later borderline CBM), 1 developed DCM-Holter and equivocal echo 365 days later (borderline CBM), 1 became equivocal echo with normal Holter results 403 days later (borderline NTproBNP)	2 (15.4%) 1 PSS (normal CBM), 1 borderline NTproBNP (634 pmol/L)	3 (25%) 2 equiv. Holter initially then developed DCM-Holter; 1 of these later showed borderline CBM, other stayed normal). 1 VT on treatment (borderline NTproBNP: 731 pmol/L)	1 (4%) (but borderline CBM: NTproBNP 690 pmol/L; hs cTnI 0.06 ng/mL) (also had cervical neuroendocrine tumour)	0	Not determined (equivocal final status)

CBM Cardiac biomarkers, CHF Congestive heart failure, echo Echocardiography, equiv Equivocal (based on echo or Holter criteria or both, hs cTnI High-sensitivity Troponin I, max Maximum, min Minimum, n number, n/a Not applicable, NTproBNP N-terminal pro-BNP, PSS Portosystemic shunt, VT Ventricular tachycardia

Abnormal cardiac biomarker results are defined as values exceeding laboratory reference range

Discordant cardiac biomarker results at presentation are those which are above the laboratory reference range in Dobermanns classified as Normal, or below reference ranges if Dobermanns classified with any form of DCM as final cardiac status.

Concordant cardiac biomarkers at presentation are defined as those consistent with the echocardiographic/Holter classification at final assessment

Borderline cardiac biomarker results were defined as high sensitivity Troponin I concentration of 0.05 to <0.07 ng/mL and N-terminal pro-BNP concentration of 550 to 734 pmol/L

Abbreviations for GROUPS: All DCM: includes data from Dobermanns with any and all forms of DCM, DCM-echo: DCM evident on echocardiography, DCM-Holter: arrhythmias noted only, DCM-both: meet both the echocardiographic and Holter criteria for diagnosis of DCM. CHF: presence of congestive heart failure (will be in Echo-DCM or Both-DCM groups; not analysed separately)

Table 3. ROC curve analysis for all forms of Dobermann DCM

	Variable	Area under curve (AUC)	Cut-offs	Sensitivity (Se)	Specificity (Sp)
All DCM	hs cTnI	0.873 (95% CI: 0.804 to 0.942)	Lab: ≥0.07 ng/mL	0.77	0.86
	NTproBNP	0.807 (95% CI: 0.725 to 0.890)	Lab: ≥735 pmol/L	0.69	0.81
All DCM: optimised Se and Sp	hs cTnI	0.873 (95% CI: 0.804 to 0.942)	0.056 ng/mL	0.84	0.84
	NTproBNP	0.807 (95% CI: 0.725 to 0.890)	626 pmol/L	0.79	0.79
Echo form of DCM (echo or both, ±CHF) (n=39) (optimised Se and Sp)	hs cTnI	0.907 (95% CI: 0.849 to 0.966)	0.062 ng/mL	0.85	0.85
	NTproBNP	0.883 (95% CI: 0.818 to 0.947)	678 pmol/L	0.81	0.81
Holter form of DCM (alone or with Echo) (n=38) (optimised Se and Sp)	hs cTnI	0.892 (95% CI: 0.818 to 0.966)	0.0615 ng/mL	0.85	0.85
	NTproBNP	0.804 (95% CI: 0.712 to 0.896)	609 pmol/L	0.78	0.78

CI Confidence intervals, hs cTnI High-sensitivity Troponin I, NTproBNP N-terminal pro-BNP, Se Sensitivity, Sp Specificity
Cut-offs for revised scoring based on optimization of both sensitivity and specificity



FIG 3. ROC curves for Dobermanns based on cardiac biomarker screening. hs cTnI: high-sensitivity Troponin I (in red); NTproBNP: N-terminal proBNP (in blue) (A, area under the curve for each ROC curve). (A) ROC curve for all forms of DCM (DCM-all) and normal Dobermanns (equivocal Dobermanns excluded from analysis). (B) ROC curve for Echo form of DCM (DCM-echo) (with or without significant arrhythmias) (equivocal Dobermanns excluded). (C) ROC curve for Holter form of DCM (DCM-Holter) (with or without echocardiographic abnormalities) (equivocal Dobermanns excluded)

Table 4. Positive and negative predictive values and likelihood ratios of cardiac biomarker tests (various cut-offs)

	Cut-off	Se	Sp	PPV	NPV	LR+	LR–
hs cTnI (ng/mL)	0.055	0.83	0.80	0.75	0.86	4.07	0.22
	0.065	0.77	0.86	0.81	0.84	5.67	0.27
	0.265	0.17	***0.98***	***0.88***	0.62	10.24	0.84
NTproBNP (pmol/L)	**603**	0.81	0.78	0.73	0.85	3.67	0.25
	623	0.79	0.79	0.72	0.83	3.58	0.27
	638	0.77	0.78	0.72	0.82	3.49	0.30
	664	0.75	0.78	0.71	0.81	3.40	0.32
	688	0.75	0.80	0.73	0.81	3.69	0.31
	2920	0.25	***0.98***	***0.92***	0.64	14.79	0.76

hs cTnI High-sensitivity cardiac Troponin I, NTproBNP N-terminal proBNP, Se Sensitivity, Sp Specificity, PPV Positive predictive value, NPV Negative predictive value, LR+ Positive likelihood ratio, LR– Negative likelihood ratio
Data for all forms of DCM included. Prevalence in this population was 42.4%, used to calculate these variables. In bold, optimal operating point for cut-offs. Bold-italics: maximum specificity and positive predictive value where data were available for all columns of this table. Italics: maximum negative predictive value

DISCUSSION

In this study, the Beckman Coulter Access hs cTnI assay (Beckman Coulter Access hsTnI assay; IDEXX Laboratories) performed better than the second generation NTproBNP assay [Cardiopet proBNP test, IDEXX Laboratories (second-generation assay); IDEXX Laboratories], based on comparisons of ROC AUCs for all forms of DCM in this population of Dobermanns. We confirmed the findings of other studies that NTproBNP had good AUCs (Wess *et al.* 2011, Singletary *et al.* 2012, Gordon *et al.* 2015) especially for the echo form of DCM. The data presented here show that the AUC, sensitivity and specificity for the Beckman Coulter Access hs cTnI assay (Beckman Coulter Access hsTnI assay; IDEXX Laboratories) was superior to the Immulite (Immulite 2000 troponin I test; Siemens Healthcare Diagnostics) assay (Wess *et al.* 2010c) and similar to the Advia Centaur ultrasensitive cTnI assay (Advia Centaur TnI-Ultra assay; Siemens Healthcare Diagnostics) (Klüser *et al.* 2019). Our results with hs cTnI (Beckman Coulter Access hsTnI assay; IDEXX Laboratories) showed better detection of DCM-echo than DCM-Holter



FIG 4. Dot Histograms for Dobermann status and cardiac biomarker concentrations. Graphs show Dobermanns with DCM (all forms) (left columns) and normal Dobermanns (right columns). (A) N-terminal pro-BNP (NTproBNP) concentrations. Red line shows the optimal cut off of 603 pmol/L to detect all forms of DCM. (B) High-sensitivity cardiac Troponin I (hs cTnI) concentrations (log_{10} scale). Red line shows the optimal cut off of 0.065 ng/mL to detect all forms of DCM

based on AUC results. This was also reported by Wess and colleagues for the Immulite assay (Immulite 2000 troponin I test; Siemens Healthcare Diagnostics) (Wess *et al.* 2010c) but not for the ultra-sensitive assay (Advia Centaur TnI-Ultra assay; Siemens Healthcare Diagnostics) (Klüser *et al.* 2019), which had similar ROC AUCs for both DCM-Echo and DCM-Holter. Troponin I is likely to be increased due to cardiomyocyte injury in all forms of DCM, and those with DCM-Echo may have more advanced disease (Wess *et al.* 2010c). In our study, when hs cTnI was compared in Dobermanns with DCM and their cause of death (sudden, cardiac or non-cardiac), there was a significant difference between groups (P=0.019) with higher hs cTnI values in sudden death or cardiac death than in dogs with DCM who died of non-cardiac causes. Klüser *et al.* (2016) noted that increased ultra-sensitive cTnI (Advia Centaur TnI-Ultra assay; Siemens Healthcare Diagnostics) was significantly higher in Dobermanns suffering a sudden cardiac death (SCD), additional to the influence of severity of left ventricular dilatation. In this study, we did not separate SCD from other forms of cardiac death, due to low numbers.

Cardiac Troponin I may be elevated due to non-cardiac disease (Wess *et al.* 2017), so a value above the cut-off does not necessarily indicate the presence of DCM. However, an abnormal result does indicate a Dobermann who would benefit from further cardiac and other veterinary examinations.

NTproBNP has been said to be not clinically useful to identify DCM-Holter (Wess *et al.* 2017). Our results using the second-generation assay appear to be slightly more discriminatory for DCM-Holter at a higher cut-off of NT-proBNP. However, for the ROC curve analysis, the DCM-Holter group included all Dobermanns meeting Holter criteria for DCM, including dogs which were abnormal on echo, which will have had increased myocardial wall stress. This group also included dogs with AF (n=5) which all also had significant ventricular arrhythmia and DCM-Echo and were in congestive heart failure.

It is interesting that this study had higher cut-offs for NTproBNP than those published previously. The results of the first-generation assay and second-generation assay are not interchangeable, as previously reported (Cahill *et al.* 2015). However, the second-generation assay was designed to give similar results to the first generation NTproBNP assay (Wess *et al.* 2017). Another study using the second-generation assay in 449 Dobermanns also gave a lower cut-off of 548 pmol/L and better AUC and sensitivity (AUC 0.91, Se 100%, Sp 80%) for echo-DCM (Gordon *et al.* 2015) than presented here. The reason for the difference is unclear, but may reflect much lower numbers in our study, or that elevated NTproBNP may reflect non-cardiac disease (*e.g.* renal or respiratory conditions), or the considerable biological day to day variability of this assay (Wess *et al.* 2017, Winter *et al.* 2017).

The second-generation assay using an EDTA plasma sample is stable at ambient temperature for 48 hours (Cahill *et al.* 2015). In our study, some dogs underwent CBM testing at dog shows at weekends, with plasma samples refrigerated or ideally frozen before shipping. It is possible that NTproBNP degraded due to variable or uncertain sample handling and delays in processing. This is therefore a limitation of this study. Sample degradation could potentially explain the inferior performance of the NTproBNP assay in this population of dogs, compared with previous publications. If this had been a factor, however, one would expect lower cut-offs rather than higher as sample degradation would have affected all samples.

It is important for a diagnostic test to have high specificity and PPV so that only dogs which may benefit from diagnostic and therapeutic interventions are identified. However, for DCM screening, high sensitivity and NPV are preferable. This permits identification of any affected individual and enables diagnostic interventions and treatments which can influence outcome (O'Grady *et al.* 2008, 2009, Summerfield *et al.* 2012). Based on the results from this study, the NPV of the hs cTnI test was

up to 0.86 (specificity 0.8), which means that up to 14% of negative tests (<0.055 ng/mL) might be false negatives (*i.e.* have DCM). For NTproBNP, the NPV was up to 0.85 (specificity 0.78), so 15% of negative tests (<603 pmol/L) are false negatives (affected cases). However, the authors propose that Dobermanns are screened by CBM screening on an annual basis, so a Dobermann with DCM should eventually be detected by the CBM screening. It must be emphasised that the CBM results do not replace the gold-standard screening of echo/Holter but they might help triage Dobermanns which benefit from full screening. The authors recommend serial screening (*e.g.* annually) in all Dobermanns, since this DCM is an acquired disease which may only be manifest in later life. Normal results from CBM analysis (and Echo or Holter screening) in a young Dobermann do not preclude the possibility that DCM may manifest in the future. Although in this study, only initial CBM results were compared with the last known phenotype, CBM data cannot be expected to predict future development of DCM in the long-term, even though this study and those by Wess *et al.* (2010c, 2011) indicated possible detection of incipient cases in the short-term.

In the 2014 UK Kennel Club survey, the Dobermanns breed had the shortest average survival time, with mean age of death 7.67 years, and the most common cause of death was cardiomyopathy, accounting for 19% of deaths (Lewis *et al.* 2018). Whilst our study shows an older mean age of death (8.95 ±2.5 years; including all causes of death), the increasing impact of DCM on the breed's longevity has considerable welfare importance. Identifying more Dobermanns in the early stages of the disease in a cost-effective way may reduce prevalence of disease if these dogs are not bred, as well as benefiting individual affected Dobermanns by allowing treatment which prolongs the asymptomatic phase of DCM (Summerfield *et al.* 2012). Future prospective studies are required to see if CBM screening and widening access to pre-DCM testing will reduce mortality or prevalence of DCM in Dobermanns.

Not many Dobermanns, especially from the normal group, underwent a repeat assessment. Therefore, the recorded cardiac status may not be accurate and some dogs may have eventually developed DCM. This study included relatively low numbers and it is possible that selecting which Dobermanns had a repeat assessment may have introduced a bias to these findings.

Troponin I and NTproBNP can be significantly elevated in various systemic diseases as noted by Wess *et al.* (2017). Although the dogs included were considered healthy by their owners, and no significant abnormalities suggesting systemic disease were noted on physical examination by the participating cardiologist, no biochemistry, haematology or thyroid function testing was undertaken to confirm health status of most Dobermanns in this study (other than clinical cases).

Multiple cardiologists, using different echocardiography machines and software, participated in the study and there was no consideration of the repeatability between cardiologists assessed as part of this study. A strength of the study was the same cardiologist carried out all the Holter analyses on the same system. However, we considered abnormal Holter recordings as those with >100 VPCs/24 hours (Wess *et al.* 2010b), in contrast to more recent recommendations, where >300 VPCs/24 hours are considered abnormal on a single recording (Wess *et al.* 2017). However, this would have not altered the classification of most dogs in this study.

In conclusion, UK Dobermanns have a high prevalence of DCM and this is of major welfare importance in the breed. CBM testing, with both high sensitivity cTnI and second generation NTproBNP assays, can be used to: screen Dobermanns for DCM in a cost-effective manner in general practice; identify individuals for further diagnostic echocardiographic and Holter assessment; and thereby permit early therapeutic intervention in the preclinical phase and removal of affected individuals from breeding programmes. The authors recommend annual CBM screening for Dobermanns, to allow detection of initially false-negative cases. The authors recommend serial testing of both hs cTnI and NTproBNP since an affected Dobermann may have a single CBM above the cut-off. In a Dobermann with an abnormal CBM result, even if Echo and Holter are initially unremarkable, repeat screening (*e.g.* in 12 months) is important in order to detect incipient cases.

Acknowledgements

This study would not have been possible without the participation of other cardiologists who screened some Dobermans as part of this study. Dr Chris Little, Sarah Smith, Dr Mark Patteson, Andrew Francis, Jo Arthur, Kieran Borgeat, Mark Oakley, Emily Dutton, Sue Roberts, Barry Cameron and the late Alistair Gibson. The author list includes cardiologists who screened eight or more Dobermanns. We are grateful to Julie West for her tireless support as Dobermann administrator of this project. In memory of Mike Window of the Dobermann Partnership, whose enthusiasm and support for the project and encouragement of Dobermann owners to participate with their dogs, made the project possible. Source of Funding for this study: The Kennel Club Charitable Trust and the Dobermann Partnership (formerly Dobermann Breed Council), plus owner contributions of £150 per dog. We acknowledge the assistance of the veterinary surgeons who attended Dobermann shows and carried out the initial physical examination and blood samples from participating Dobermanns. IDEXX ran the CBMs at discounted cost for this study. The authors are especially grateful to Anne M. Porritt at IDEXX Laboratories, Wetherby, UK for her help and Graham Bilbrough of IDEXX for his guidance at the start of the project.

Conflict of interest

JLA and PFM are telemedicine consultants for IDEXX laboratories. The authors declare no other potential conflicts of interest.

References

Cahill, R. J., Pigeon, K., Strong-Townsend, M. I., *et al.* (2015) Analytical validation of a second-generation immunoassay for the quantification of N-terminal pro-B-type natriuretic peptide in canine blood. *Journal of Veterinary Diagnostic Investigation* **27**, 61-67

Gordon, S., Braz-Ruivo, L., Drourr, L., *et al.* (2013) Prospective evaluation of NT-proBNP, high sensitivity troponin I and PDK4 for the detection of occult DCM in 225 Doberman Pinschers. Proceedings of the American College of Veterinary Internal Medicine Forum, 12-15 June 2013 Seattle, WA, USA. https://www.vin.com/doc/?id=5820367. Accessed June 25, 2020

Gordon, S. G., Estrada, A. H., Braz-Ruivo, L., *et al.* (2015) Evaluation of NTproBNP, High Sensitivity Troponin I and PDK4 for the Detection of Occult DCM: A Prospective

Study in 449 Doberman Pinschers. European College of Veterinary Intermal Medicine (Companion Animals) Congress, 10-12 September 2015. Lisbon, Portugal. p 365.
Klüser, L., Holler, P. J., Simak, J., *et al*. (2016) Predictors of sudden cardiac death in Doberman pinschers with dilated cardiomyopathy. *Journal of Veterinary Internal Medicine* **30**, 722-732
Klüser, L., Maier, E. T. & Wess, G. (2019) Evaluation of a high-sensitivity cardiac troponin I assay compared to a first-generation cardiac troponin I assay in Doberman pinschers with and without dilated cardiomyopathy. *Journal of Veterinary Internal Medicine* **33**, 54-63
Lewis, T. W., Wiles, B. M., Llewellyn-Zaidi, A. M., *et al*. (2018) Longevity and mortality in kennel Club registered dog breeds in the UK in 2014. *Canine Genetics and Epidemiology* **5**, 10
Mausberg, T. B., Wess, G., Simak, J., *et al*. (2011) A locus on chromosome 5 is associated with dilated cardiomyopathy in Doberman pinschers. *PLoS One* **6**, e20042
Meurs, K. M., Lahmers, S., Keene, B. W., *et al*. (2012) A splice site mutation in a gene encoding for PDK4, a mitochondrial protein, is associated with the development of dilated cardiomyopathy in the Doberman pinscher. *Human Genetics* **131**, 1319-1325
Meurs, K. M., Friedenberg, S. G., Kolb, J., *et al*. (2019) A missense variant in the titin gene in Doberman pinscher dogs with familial dilated cardiomyopathy and sudden cardiac death. *Human Genetics* **138**, 515-524
O'Grady, M. R., Minors, S. L., O'Sullivan, M. L., *et al*. (2008) Effect of pimobendan on case fatality rate in Doberman pinschers with congestive heart failure caused by dilated cardiomyopathy. *Journal of Veterinary Internal Medicine* **22**, 897-904
O'Grady, M. R., O'Sullivan, M. L., Minors, S. L., *et al*. (2009) Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman pinschers. *Journal of Veterinary Internal Medicine* **23**, 977-983
Owczarek-Lipska, M., Mausberg, T. B., Stephenson, H., *et al*. (2013) A 16-bp deletion in the canine PDK4 gene is not associated with dilated cardiomyopathy in a European cohort of Doberman pinschers. *Animal Genetics* **44**, 239
Oyama, M. A. & Sisson, D. D. (2004) Cardiac troponin-I concentration in dogs with cardiac disease. *Journal of Veterinary Internal Medicine* **18**, 831-839
Simpson, S., Edwards, J., Emes, R. D., *et al*. (2015) A predictive model for canine dilated cardiomyopathy – a meta-analysis of Doberman pinscher data. *PeerJ* **3**, e842
Singletary, G. E., Morris, N. A., Lynne O'Sullivan, M., *et al*. (2012) Prospective evaluation of NT-proBNP assay to detect occult dilated cardiomyopathy and predict survival in Doberman pinschers. *Journal of Veterinary Internal Medicine* **26**, 1330-1336
Summerfield, N. J., Boswood, A., O'Grady, M. R., *et al*. (2012) Efficacy of pimobendan in the prevention of congestive heart failure or sudden death in Doberman pinschers with preclinical dilated cardiomyopathy (the PROTECT study). *Journal of Veterinary Internal Medicine* **26**, 1337-1349
Wess, G., Maurer, J., Simak, J., *et al*. (2010a) Use of Simpson's method of disc to detect early echocardiographic changes in Doberman pinschers with dilated cardiomyopathy. *Journal of Veterinary Internal Medicine* **24**, 1069-1076
Wess, G., Schulze, A., Butz, V., *et al*. (2010b) Prevalence of dilated cardiomyopathy in Doberman pinschers in various age groups. *Journal of Veterinary Internal Medicine* **24**, 533-538
Wess, G., Simak, J., Mahling, M., *et al*. (2010c) Cardiac troponin I in Doberman pinschers with cardiomyopathy. *Journal of Veterinary Internal Medicine* **24**, 843-849
Wess, G., Butz, V., Mahling, M., *et al*. (2011) Evaluation of N-terminal pro-B-type natriuretic peptide as a diagnostic marker of various stages of cardiomyopathy in Doberman pinschers. *American Journal of Veterinary Research* **72**, 642-649
Wess, G., Domenech, O., Dukes-McEwan, J., *et al*. (2017) European Society of Veterinary Cardiology screening guidelines for dilated cardiomyopathy in Doberman pinschers. *Journal of Veterinary Cardiology* **19**, 405-415
Winter, R. L., Saunders, A. B., Gordon, S. G., *et al*. (2017) Biologic variability of N-terminal pro-brain natriuretic peptide in healthy dogs and dogs with myxomatous mitral valve disease. *Journal of Veterinary Cardiology* **19**, 124-131